Market Cap
$2.6B
HCM
HUTCHMED (China) Ltd
$14.32 ▼ -1.72%
Prev close $14.57Market cap$2.6B
ConsensusStrong Buy
12-mo target$22.01 (+53.7%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)7 New Institutional Positions3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on HCM right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
37 funds
Inst. Value
$39.9M
Inst. Activity
7 buys / 3 sells
Social Sentiment
39° Cool
SEC Reports
11
Press Releases
7
Price chart 30d +18.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 fda
Sep 3, 2026 SEC HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumor
HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibod
6-K — Impact 7/10
HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) si
6-K — Impact 7/10
HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnost
6-K — Impact 2/10
HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) s
Impact 8/10
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
194,472 shares ($2.1M)
Jun 30, 2026 Inst.
Jun 25, 2026 Press Vanguard Personalized Indexing Management, — DOUBLED
42,599 shares ($458.4K)
HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholan
Impact 7/10
Analyst ratings buy % -7.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 28 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Jul 7, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 13 | 5 | 0 | 0 | 82% | |
| Aug 1, 2026 | 10 | 12 | 4 | 0 | 0 | 85% | |
| Jul 1, 2026 | 10 | 13 | 3 | 0 | 0 | 88% | |
| Jun 1, 2026 | 10 | 13 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Apr 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Mar 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Feb 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% |
Price targets
Where 14 covering analysts think HCM trades over the next 12 months.
$22.01 +53.7% upside Strong Buy
Current$14.32 Low$13.60 Median$19.50 High$40.40 14 analysts
$13.60$40.40
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood -20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
39°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 7 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 5.2/10.Plus 7 press releases.
BULLISH6-K7/10
HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-cla
Sep 3, 2026
BULLISH6-K7/10
HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRI
Aug 31, 2026
NEUTRAL6-K2/10
HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of
Aug 18, 2026
BULLISH6-K7/10
HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGR
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
fda
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after
Sep 28, 2026
other
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibition First-in-class KRAS-payload leveraging synchronized EGFR inhibition
Sep 24, 2026
fda
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13)
Sep 3, 2026
other
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials
Aug 31, 2026
fda
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.22 | $0.02–$0.40 | -91.5% | +40.2% | 1↑ 0↓ | $0.6B | 6 |
| Next FY | $0.26 | $0.07–$0.62 | 16.8% | +6.3% | 1↑ 0↓ | $0.7B | 6 |
Institutional ownership
Which big funds own HCM (from quarterly 13F filings) and who is adding or trimming.
37 institutional holders with $39.9M total value (3,709,584 shares) as of 2026-Q2. Top holders: SCHRODER, Allianz, STATE. Net buying activity: 7 institutions added/increased vs 3 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1,477,494 | $15.8M | 39.7% | TRIM -35.2% |
| Allianz Asset Management GmbH | 674,511 | $7.3M | 18.2% | — |
| STATE STREET CORP | 313,611 | $3.4M | 8.5% | — |
| M&G Plc | 242,791 | $2.7M | 6.7% | ADD +26.7% |
| Amundi | 204,385 | $2.2M | 5.5% | ADD +41.9% |
| JANE STREET GROUP, LLC | 194,472 | $2.1M | 5.2% | DOUBLED +154.2% |
| RENAISSANCE TECHNOLOGIES LLC | 130,200 | $1.4M | 3.5% | — |
| BNP PARIBAS FINANCIAL MARKETS | 104,425 | $1.1M | 2.8% | DOUBLED +239.2% |
| TWO SIGMA INVESTMENTS, LP | 63,248 | $680.5K | 1.7% | TRIM -41.5% |
| UBS Group AG | 44,183 | $475.4K | 1.2% | TRIM -26.3% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JANE STREET GROUP, LLC | DOUBLED | 76,514 | 194,472 | +154.2% | $2.1M |
| Vanguard Personalized Indexing Management, LLC | DOUBLED | 20,425 | 42,599 | +108.6% | $458.4K |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 55,969 | 38,967 | -30.4% | $419.3K |
| Vident Advisory, LLC | ADD | 17,726 | 26,584 | +50.0% | $286.0K |
| ROYAL BANK OF CANADA | DOUBLED | 2,660 | 5,428 | +104.1% | $58.0K |
| Russell Investments Group, Ltd. | DOUBLED | 42 | 4,821 | +11378.6% | $51.6K |
| ASSETMARK, INC | DOUBLED | 187 | 812 | +334.2% | $8.7K |
| Arax Advisory Partners | DOUBLED | 103 | 400 | +288.3% | $4.3K |
| SIMPLEX TRADING, LLC | TRIM | 506 | 304 | -39.9% | $3.3K |
| OSAIC HOLDINGS, INC. | TRIM | 764 | 231 | -69.8% | $2.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 8 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 5,176 | — | — |
| May 20, 2026 | Chiu Lorenso | Deputy Chief Financial Officer | J | 8,863 | — | — |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 132,864 | — | — |
| May 20, 2026 | Su Wei-guo | CEO and CSO | J | 75,140 | — | — |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,445 | — | — |
| May 20, 2026 | Nixon Charles George Rupert | Group General Counsel | J | 7,644 | — | — |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 30,157 | — | — |
| May 20, 2026 | Cheng Chig Fung | Acting CEO and CFO | J | 26,307 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HCM.
Shares short
230,030
Settlement Sep 15, 2026
Change vs prior
+14.4%
Semi-monthly cycle
Days to cover
1.8
At avg daily volume
Of shares outstanding
≈0.1%
Estimate — not % of float
All HCM filing & press-release reports (18)
- 6-K reportSep 3, 2026
- 6-K reportAug 31, 2026
- 6-K reportAug 18, 2026
- 6-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 3, 2026
- 6-K reportJun 30, 2026
- PRESS-RELEASE reportJun 30, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 26, 2026
- PRESS-RELEASE reportJun 25, 2026
- 6-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportApr 9, 2026
- PRESS-RELEASE reportMar 23, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 4, 2026